Work

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

Year: 2024

Type: article

Abstract: Not available.

Source: Haematologica

DOI: 10.3324/haematol.2024.285553

Authors: Morag Griffin, Shreyans Gandhi, Richard J. Kelly, Talha Munir, Roochi Trikha, Eden Hicks, Deepak Jain, Masayo Ogawa, Ji Yu, Petra Muus, Austin G. Kulasekararaj

Institutions: Leeds Teaching Hospitals NHS Trust, St James's University Hospital, National Institute for Health and Care Research, King's College Hospital, Wellcome Trust, Alexion Pharmaceuticals (United States), King's College London

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,157

Funders: AstraZeneca, Alexion Pharmaceuticals

OpenAlex ID: W4404806826

FWCI: 0.278

Cites: 13

Cited by: 2

Related to: 10